Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world’s toughest diseases. We helped establish the biotechnology industry more than 40 years ago and remain on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today. Our investment in research and development over the past five years has yielded a robust pipeline that builds on our existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.

Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and we are also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.

The Rhythm
of Life

Watch Video

Reaching Seriously Ill Patients Worldwide

We have a presence in approximately 100 countries and regions worldwide and our innovative medicines have reached millions of people in the fight against serious illnesses. We focus on four therapeutic areas, oncology, inflammation, general medicine and rare disease, delivering innovative medicines to help people live longer, fuller, happier lives.

Investing in Science and Innovation

We pursue new ways to do science using tools like AI, generative biology and human data to discover what is not yet known and develop new precision medicines to fight the world’s toughest diseases.

Making Medicines Safely and Reliably

Many of Amgen's medicines are made through a highly complex process involving living cells. Our commitment is to deliver for "every patient, every time", and we have a long-running reputation for the reliability of our supply chain.

Operating Responsibly

Making a positive difference in the world is at the heart of what we do at Amgen — and it goes beyond making vital medicines. We also help build a better world by focusing on environmental, social and governance (ESG) issues that matter most to our business and our stakeholders.

In This Section

Letter to Our Shareholdersicon

Amgen performed well in 2023, serving millions of patients around the world with our innovative, life-changing medicines; advancing many promising new first-in-class molecules in our pipeline; completing a significant acquisition that establishes us as a leader in treating rare diseases; and delivering strong financial performance.

Mission and Valuesicon

Amgen strives to serve patients by transforming the promise of science and biotechnology into therapies that have the power to restore health or save lives.

Leadershipicon

As one of the early pioneers of the biotech industry, Amgen's innovative and inspirational leadership is a core part of our social architecture.

How We Operateicon

At Amgen, we are relentless in applying the highest ethical standards to everything we do.

Awards and Accoladesicon

Amgen has been the recipient of numerous awards and accolades over the years, ranging from recognition of our pioneering science and innovation, philanthropy and corporate social responsibility to our commitment to being a great place to work.

Amgen Historyicon

A biotechnology innovator since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies and has reached millions of patients around the world.

RELATED LINKS